典型文献
Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study
文献摘要：
Background::To determine the prevalence and prognostic impact of hepatopulmonary syndrome (HPS) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).Methods::Fifty-four patients with unresectable HCC undergoing TACE between December 2014 and December 2015 were prospectively screened for HPS and were followed up for a maximum of 2 years or until the end of this prospective study.Results::Nineteen of the 54 (35.2%) patients were considered to have HPS, including one (5.3%) with severe HPS, nine (47.4%) with moderate HPS, and nine (47.4%) with mild HPS. The median overall survival (OS) was 10.1 (95% confidence interval [CI], 3.9–16.3) months for patients with HPS and 15.1 (95% CI, 7.3–22.9) months for patients without HPS, which is not a significant difference (
P = 0.100). The median progression-free survival was also not significantly different between patients with and without HPS (5.2 [95% CI, 0–12.8]
vs. 8.4 [95% CI, 3.6–13.1] months;
P = 0.537). In the multivariable Cox regression analyses, carbon monoxide diffusing capacity (hazard ratio [HR] = 1.033 [95% CI, 1.003–1.064];
P = 0.028) and Child-Pugh class (HR = 1.815 [95% CI, 1.011–3.260];
P = 0.046) were identified to be the independent prognostic factors of OS.
Conclusion::Mild or moderate HPS is common in patients with unresectable HCC undergoing TACE, but it does not seem to have a significant prognostic impact.
文献关键词：
Hepatocellular carcinoma;Hepatopulmonary syndrome;Chemoembolization;Therapeutic;Prognosis;Prevalence
中图分类号：
作者姓名：
Zhao He;Tsauo Jiaywei;Zhang Xiaowu;Ma Huaiyuan;Weng Ningna;Yang Zhengqiang;Li Xiao
作者机构：
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
文献出处：
引用格式：
[1]Zhao He;Tsauo Jiaywei;Zhang Xiaowu;Ma Huaiyuan;Weng Ningna;Yang Zhengqiang;Li Xiao-.Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study)[J].中华医学杂志（英文版）,2022(17):2043-2048
A类：
Hepatopulmonary
B类：
Prevalence,prognostic,impact,hepatopulmonary,syndrome,patients,unresectable,hepatocellular,carcinoma,undergoing,transarterial,chemoembolization,cohort,study,Background,To,determine,prevalence,HPS,HCC,TACE,Methods,Fifty,four,between,December,were,prospectively,screened,followed,up,maximum,years,until,this,Results,Nineteen,considered,have,including,one,severe,nine,moderate,mild,median,overall,survival,OS,was,confidence,interval,months,without,which,not,difference,progression,free,also,significantly,different,In,multivariable,Cox,regression,analyses,carbon,monoxide,diffusing,capacity,hazard,ratio,Child,Pugh,class,identified,independent,factors,Conclusion,Mild,common,but,does,seem,Hepatocellular,Chemoembolization,Therapeutic,Prognosis
AB值：
0.488646
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
